When it comes to weight loss, moving the scale can feel daunting. You're trying to figure out the best diet plan, exercise ...

New-generation GLP-1 drugs, such as retatrutide, are achieving higher rates of weight loss. How much weight is too much and ...

Retatrutide shows big weight loss potential but isn’t FDA-approved. Here’s what to know about its safety and legal risks.

A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity, ...

Retatrutide altered circulating metabolites and lipids linked to fatty acid oxidation and insulin resistance in people with ...

Retatrutide, Eli Lilly’s new experimental drug, helped some participants lose up to 28 percent of their body weight in clinical trials.

Eli Lilly (NYSE:LLY) announced a US$3.8b series of acquisitions in vaccines, including Curevo, LimmaTech Biologics, and ...

But while Ozempic is arguably the most recognizable drug in its class, it isn’t the only medication approved for weight management. Others include Wegovy and Saxenda, while newer drugs like ...

Eli Lilly's Retatrutide delivered record-breaking weight loss in trials, offering new hope for people struggling with obesity ...

Eli Lilly LLY announced positive top-line results from a late-stage study evaluating its next-generation, experimental ...

It's said to be three times as effective as its famous predecessors ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.